BRIEF-Eli Lilly down in premarket after Alzheimer's treatment update

NEW YORK Wed Dec 12, 2012 7:37am EST

NEW YORK Dec 12 (Reuters) - Eli Lilly and Co : * Down 3.2 percent to $49 in premarket after the company said it plans to conduct a big new trial of its experimental Alzheimer's disease treatment among patients with mild symptoms but did not plan to seek U.S. apporval at this time

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.